Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 4,285 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $25.00, for a total value of $107,125.00. Following the completion of the transaction, the director directly owned 25,107 shares in the company, valued at $627,675. This represents a 14.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Enliven Therapeutics Stock Down 3.7%

Enliven Therapeutics stock opened at $25.03 on Tuesday. The stock has a 50-day moving average price of $19.17 and a 200 day moving average price of $19.97. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -13.60 and a beta of 0.41. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ELVN shares. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. BNP Paribas Financial Markets boosted its stake in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares in the last quarter. Quantbot Technologies LP increased its stake in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares in the last quarter. AlphaQuest LLC acquired a new position in Enliven Therapeutics in the 3rd quarter worth about $96,000. Tower Research Capital LLC TRC boosted its position in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after purchasing an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its holdings in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics News Roundup

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: MSN published a piece noting Enliven has rising relative price strength, a technical signal that can attract momentum traders and institutional interest. Article Title
• Neutral Sentiment: Short-interest data reported an anomalous reading (zero shares reported as of Jan 12), producing no clear bearish signal; the metric is effectively neutral/uncertain and unlikely to explain today’s move on its own.
• Negative Sentiment: Chief insider selling: CEO/insider Joseph P. Lyssikatos completed multiple sales (41,302 shares at ~$24.05 and 91,198 shares at ~$27.22), generating roughly $3.47M in proceeds and reducing his stake by double-digit percentages in those transactions — a notable supply event that can pressure the share price. SEC Filing
• Negative Sentiment: Director sales: Richard A. Heyman sold 9,635 shares (avg $25.03) and 4,285 shares (avg $25.00) across Jan 8–9, totaling ~13,920 shares and ≈$348k — further insider selling that likely added downward pressure. SEC Filing

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.